Dosing Strategy for Cefepime and Vancomycin in Community-Acquired Pneumonia
For moderate to severe community-acquired pneumonia, use cefepime 1-2 g IV every 8-12 hours for 10 days, and if MRSA coverage with vancomycin is needed, dose at least 1 g IV every 8 hours (not every 12 hours) to achieve therapeutic trough levels of 15-20 mg/L. 1, 2
Cefepime Dosing
The FDA-approved dosing for moderate to severe pneumonia is straightforward 1:
- Standard dose: 1-2 g IV every 8-12 hours
- Duration: 10 days
- Administration: Infuse over approximately 30 minutes
For Pseudomonas aeruginosa specifically, use the higher intensity regimen of 2 g IV every 8 hours 1. This is critical because inadequate dosing against Pseudomonas leads to treatment failure.
Renal Adjustment for Cefepime
Adjust doses when creatinine clearance ≤60 mL/min 1:
- CrCl 30-60: 2 g every 24 hours (or 2 g every 12 hours for severe infections)
- CrCl 11-29: 1 g every 24 hours
- CrCl <11: 500 mg every 24 hours
- Hemodialysis: 1 g on day 1, then 500 mg every 24 hours (give after dialysis)
Vancomycin Dosing
The traditional 1 g every 12 hours dosing is inadequate for pneumonia in critically ill patients. Research demonstrates that this regimen fails to achieve target trough concentrations of 15-20 mg/L needed for MRSA pneumonia 2.
Recommended Vancomycin Strategy:
- Dose: At least 1 g IV every 8 hours (not every 12 hours)
- Target trough: 15-20 mg/L
- Rationale: In a study of critically ill trauma patients with MRSA pneumonia, only 23.5% achieved therapeutic troughs with 1 g every 8 hours, while ZERO patients achieved target levels with 1 g every 12 hours 2
Critical pitfall: The every-12-hour dosing produces mean troughs of only 6.8 mg/L versus 11.1 mg/L with every-8-hour dosing—both subtherapeutic, but the latter at least approaches the target 2. Many patients will require even higher doses or continuous infusion strategies.
Duration Considerations
While the FDA label specifies 10 days for cefepime in pneumonia 1, emerging evidence supports shorter durations when patients achieve clinical stability:
- 3 days if clinically stable by day 3 3, 4
- 5 days if stability achieved by day 5 3
- 7-10 days for uncomplicated cases without early stability 3, 5
However, the 2019 IDSA/ATS guideline does not specify exact durations for severe CAP requiring IV therapy 6, and the FDA label remains at 10 days 1. For severe pneumonia requiring cefepime and vancomycin, err toward 7-10 days unless rapid clinical improvement allows earlier discontinuation.
Important Caveats
Cefepime is NOT standard empiric therapy for typical CAP. The 2019 IDSA/ATS guideline recommends beta-lactam/macrolide combinations (like ceftriaxone plus azithromycin) or respiratory fluoroquinolones for hospitalized CAP without risk factors for resistant pathogens 6. Cefepime is reserved for:
- Suspected Pseudomonas (structural lung disease, recent hospitalization, prior antibiotics)
- Healthcare-associated pneumonia
- Severe sepsis requiring broader coverage
Vancomycin is only indicated when MRSA is suspected (recent hospitalization, MRSA colonization, severe necrotizing pneumonia, post-influenza pneumonia, or local high MRSA prevalence).
Monitor vancomycin troughs before the 4th dose and adjust accordingly—most patients will need doses higher than 1 g every 8 hours to consistently achieve 15-20 mg/L troughs.